Rznomics joins Lilly Gateway Labs to advance RNA programmes
Rznomics says its participation in Lilly Gateway Labs is intended to accelerate discovery and development of RNA therapeutic candidates. The announcement concerns a product, collaboration or production plan; it does not by itself establish clinical benefit or verified scale-up performance.
- Published by
- GEN — Genetic Engineering & Biotechnology News
- Evidence type
- Industry
GEN reports: Rznomics says its participation in Lilly Gateway Labs is intended to accelerate discovery and development of RNA therapeutic candidates.
The announcement concerns a product, collaboration or production plan; it does not by itself establish clinical benefit or verified scale-up performance. Consult the linked GEN report for the source organisation’s full announcement.
Let's engineer the next delivery breakthrough together
We co-develop nanocarrier and biosensing programmes with pharma, biotech and academic groups — from target selection through GMP supply.
Prefer to talk it through? Book a 30-minute discovery call